US equities |
MU $983.23 ▲+5.86% META $612.49 ▼-1.24% GOOGL $324.89 ▲+1.34% NVDA $215.38 ▼-1.17% MSFT $531.01 ▼-0.06% TSLA $404.22 ▼-0.80% SPCX $145.23 ▼-2.25% SNDK $1,404.77 ▲+7.66%
FinancialContent

Caribou Biosciences, Inc. - Common Stock (NQ:CRBU)

0.4894 +0.0287 (+6.23%)
Delayed Quote Updated: 4:00 PM EDT, Oct 28, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Caribou Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗
Via Chartmill
What's going on in today's session ↗
Via Chartmill
Wednesday's session: gap up and gap down stocks ↗
Via Chartmill
Wondering what's happening in today's pre-market session? ↗
Via Chartmill
Caribou Biosciences Stock Soars Pre-market On Positive Early Trial Data For Cancer Treatments ↗
Via Stocktwits
Curious about the stocks that are showing activity after the closing bell on Tuesday? ↗
Via Chartmill
News headline image
Caribou Biosciences to Evaluate Strategic Alternatives
From Caribou Biosciences, Inc.
Via GlobeNewswire
News headline image
Caribou Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update
From Caribou Biosciences, Inc.
Via GlobeNewswire
News headline image
Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
From Caribou Biosciences, Inc.
Via GlobeNewswire
News headline image
After CAR-T, the Next Frontier in Cancer Immunotherapy May Belong to a Different Immune Cell
From Equity Insider
Via GlobeNewswire
News headline image
Caribou Biosciences Reports Long-Term Vispa-cel Data in Second-line Large B Cell Lymphoma at EHA 2026
From Caribou Biosciences, Inc.
Via GlobeNewswire
News headline image
Caribou Biosciences Reports Dose Escalation Durability Data for CB-011 at the 2026 European Hematology Association (EHA) Annual Meeting
From Caribou Biosciences, Inc.
Via GlobeNewswire
News headline image
Caribou Biosciences Says CRISPR CAR-T Is Pivotal-Ready, CB-011 Data Nears ↗
Caribou Biosciences (NASDAQ:CRBU) Chief Executive Officer Rachel Haurwitz said the company is advancing two CRISPR-enabled, off-the-shelf CAR T cell therapy programs, with its lymphoma candidate... 
Via MarketBeat
News headline image
Caribou Biosciences to Participate in the 2026 Jefferies Global Healthcare Conference
From Caribou Biosciences, Inc.
Via GlobeNewswire
News headline image
Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference
From Caribou Biosciences, Inc.
Via GlobeNewswire
News headline image
Caribou Biosciences to Highlight Vispa-cel and CB-011 Programs During Oral Presentations at the 2026 European Hematology Association (EHA) Annual Meeting
From Caribou Biosciences, Inc.
Via GlobeNewswire
News headline image
Caribou Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update
From Caribou Biosciences, Inc.
Via GlobeNewswire
News headline image
Caribou Biosciences to Participate in the BofA Securities 2026 Health Care Conference
From Caribou Biosciences, Inc.
Via GlobeNewswire
News headline image
Caribou Biosciences Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) Designation to CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy
From Caribou Biosciences, Inc.
Via GlobeNewswire
News headline image
Caribou Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
From Caribou Biosciences, Inc.
Via GlobeNewswire
News headline image
Caribou Biosciences to Participate in Upcoming Investor Conferences
From Caribou Biosciences, Inc.
Via GlobeNewswire
News headline image
Caribou Biosciences Announces Late-Breaking Presentations at the 2026 Tandem Meetings of ASTCT® and CIBMTR®
From Caribou Biosciences, Inc.
Via GlobeNewswire
News headline image
Precision's Payoff: Targeted Therapies Drive $131B Solid Tumor Market Surge
Issued on behalf of GT Biopharma, Inc. 
From Equity Insider
Via GlobeNewswire
News headline image
Caribou Biosciences to Host In-Person and Virtual KOL Event at ASH 2025
From Caribou Biosciences, Inc.
Via GlobeNewswire
News headline image
Caribou Biosciences Reports Third Quarter 2025 Financial Results and Provides Business Update
From Caribou Biosciences, Inc.
Via GlobeNewswire
News headline image
Caribou Biosciences to Participate in Upcoming Investor Conferences
From Caribou Biosciences, Inc.
Via GlobeNewswire
News headline image
Aprea Therapeutics (Nasdaq: APRE) Transforms Cutting-Edge Science into Next-Generation Cancer Therapies – More Stocks Inside
Via AB Newswire
Topics Artificial Intelligence
News headline image
Why Is CRISPR Genome-Editing Firm Caribou Biosciences Stock Trading Higher Today? ↗
Caribou Biosciences shares rose after its CAR-T therapies showed high response rates and durable remissions in lymphoma and myeloma trials. 
Via Benzinga
News headline image
Gapping stocks in Monday's session ↗
In today's session, there are notable price gaps in the US markets on Monday. Take a closer look at the stocks that are gap up and gap down. 
Via Chartmill
News headline image
Discover the top movers in Monday's pre-market session. ↗
As we await the opening of the US market on Monday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9 10 Next >